These observations suggest that survivin may be a potential therapeutic target for treating pancreatic cancer, and that our PPCLs developed from PDX tumors provide a suitable model to evaluate this hypothesis. The gene discussed is BIRC5; the disease is familial pancreatic carcinoma.